Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00819663 · ClinicalTrials.gov registry record

Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography

A clinical trial of Crohn's Disease, sponsored by Mayo Clinic.

Completed
Registry status
67
Enrollment target
1
Study location

NCT00819663 is a study of Crohn's Disease that has completed, run by Mayo Clinic. The registered enrollment target is 67 participants, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00819663, a study of Crohn's Disease, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
67 participants
Enrollment target
1
Study location

Study Summary

Anti-TNF therapy induces intestinal wall remodeling that correlates with clinical response and can be detected in patients undergoing serial computed tomography enterography (CTE).

Conditions Studied

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2009-02
Est. Completion 2010-08

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT00819663

The ClinicalTrials.gov registry entry for NCT00819663 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (97% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 0 interventions.

NCT00819663 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT00819663 about?

NCT00819663 is a clinical study titled "Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography". Anti-TNF therapy induces intestinal wall remodeling that correlates with clinical response and can be detected in patients undergoing serial computed tomography enterography (CTE).

What is the current status of trial NCT00819663?

This trial is currently completed. The enrollment target is 67 participants. The study started on 2009-02. Estimated completion is 2010-08.

What conditions does trial NCT00819663 study?

This clinical trial studies the following conditions: Crohn's Disease.

Who is sponsoring clinical trial NCT00819663?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00819663 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.